Indian CRISPR startup CrisprBits closed a $3 million pre‑Series A round led by Spectrum Impact to expand CRISPR‑based diagnostics and gene‑editing R&D. The financing will support product development, assay validation and early commercial efforts in molecular diagnostics and applied CRISPR technologies. CrisprBits plans to deploy capital to scale laboratory capacity, advance regulatory readiness and strengthen partnerships to commercialize point‑of‑care and laboratory diagnostics leveraging CRISPR enzymology. The raise reflects sustained investor interest in CRISPR diagnostics as a nearer‑term commercial opportunity relative to therapeutic gene editing. Market participants view the round as emblematic of regional life‑science ecosystems maturing and of venture activity targeting platform companies that can serve diagnostics, agriculture and industrial biotech segments.